A Nonhuman Primate Model of Early Alzheimer's Disease Pathologic Change: Implications for Disease Pathogenesis

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2018 Nov 24

PMID 30467082

Citations 52

Authors

Caitlin S Latimer

Carol A Shively

C Dirk Keene

Matthew J Jorgensen

Rachel N Andrews

Thomas C Register

Thomas J Montine

Angela M Wilson

Bryan J Neth

Akiva Mintz

Joseph A Maldjian

Christopher T Whitlow

Jay R Kaplan

Suzanne Craft

Affiliations

Soon will be listed here.

Abstract

Introduction: Nonhuman primates may serve as excellent models of sporadic age-associated brain β-amyloid deposition and Alzheimer's disease pathologic changes. We examined whether a vervet nonhuman primate model recapitulated pathologic, physiologic, and behavioral features of early Alzheimer's disease.

Methods: Nine middle-aged (mean = 11.2 years) and nine aged (mean = 21.7 years) female vervet/African green monkeys underwent cerebrospinal fluid collection, gait speed measurement, and neuroimaging before neuropathologic assessment.

Results: β-amyloid plaques were identified in all aged vervets and paired helical filament tau immunoreactivity was observed in all animals. Cerebrospinal fluid β-amyloid and gait speed correlated negatively with age and plaque density. Greater plaque and paired helical filament tau burden predicted reduced volumes and CMRg in several brain regions.

Discussion: We observed a coordinated set of relationships among neuropathologic, cerebrospinal fluid, imaging, and behavioral modalities consistent with early Alzheimer's disease. Our results support future use of the vervet model to explore disease mechanisms, biomarkers, and novel therapeutic strategies.

Citing Articles

Characterizing plasma and cerebrospinal fluid biomarkers relevant to neurodegeneration in captive olive baboons (Papio anubis).

Neal S, Chitta S, Magden E, Simmons J PLoS One. 2025; 20(2):e0318173.

PMID: 39946349 PMC: 11825030. DOI: 10.1371/journal.pone.0318173.

Ex vivo functional whole organ in biomedical research: a review.

Subbiahanadar Chelladurai K, Selvan Christyraj J, Rajagopalan K, Vadivelu K, Chandrasekar M, Das P J Artif Organs. 2024; .

PMID: 39592544 DOI: 10.1007/s10047-024-01478-4.

Brain aging and Alzheimer's disease, a perspective from non-human primates.

Isidro F Aging (Albany NY). 2024; 16(20):13145-13171.

PMID: 39475348 PMC: 11552644. DOI: 10.18632/aging.206143.

Amyloid-Beta, Tau, and Microglial Activation in Aged Felid Brains.

Kulik V, Edler M, Raghanti M, Imam A, Sherwood C J Comp Neurol. 2024; 532(11):e25679.

PMID: 39474737 PMC: 11572721. DOI: 10.1002/cne.25679.

Alzheimer disease-like neuropathologic changes in a geriatric baboon ().

Harrison W, Cline J, Caudell D, Huber H, Shively C, Register T J Vet Sci. 2024; 25(5):e60.

PMID: 39231785 PMC: 11450389. DOI: 10.4142/jvs.24080.

References

Jasinska A, Schmitt C, Service S, Cantor R, Dewar K, Jentsch J . Systems biology of the vervet monkey. ILAR J. 2013; 54(2):122-43. PMC: 3814400. DOI: 10.1093/ilar/ilt049. View

Rohlfing T, Kroenke C, Sullivan E, Dubach M, Bowden D, Grant K . The INIA19 Template and NeuroMaps Atlas for Primate Brain Image Parcellation and Spatial Normalization. Front Neuroinform. 2012; 6:27. PMC: 3515865. DOI: 10.3389/fninf.2012.00027. View

Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View

Braak H, Braak E . Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995; 16(3):271-8; discussion 278-84. DOI: 10.1016/0197-4580(95)00021-6. View

Mielke M, Roberts R, Savica R, Cha R, Drubach D, Christianson T . Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci. 2012; 68(8):929-37. PMC: 3712358. DOI: 10.1093/gerona/gls256. View

Wennberg A, Savica R, Hagen C, Roberts R, Knopman D, Hollman J . Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. J Am Geriatr Soc. 2016; 65(4):792-799. PMC: 5397339. DOI: 10.1111/jgs.14670. View

Maass A, Lockhart S, Harrison T, Bell R, Mellinger T, Swinnerton K . Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. J Neurosci. 2017; 38(3):530-543. PMC: 5777108. DOI: 10.1523/JNEUROSCI.2028-17.2017. View

Thal D, Holzer M, Rub U, Waldmann G, Gunzel S, Zedlick D . Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol. 2000; 163(1):98-110. DOI: 10.1006/exnr.2000.7380. View

Kalinin S, Willard S, Shively C, Kaplan J, Register T, Jorgensen M . Development of amyloid burden in African Green monkeys. Neurobiol Aging. 2013; 34(10):2361-9. PMC: 3706498. DOI: 10.1016/j.neurobiolaging.2013.03.023. View

10.

Lemere C, Beierschmitt A, Iglesias M, Spooner E, Bloom J, Leverone J . Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004; 165(1):283-97. PMC: 1618542. DOI: 10.1016/s0002-9440(10)63296-8. View

11.

Toledo J, Cairns N, Da X, Chen K, Carter D, Fleisher A . Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun. 2013; 1:65. PMC: 3893373. DOI: 10.1186/2051-5960-1-65. View

12.

Thal D, Rub U, Orantes M, Braak H . Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002; 58(12):1791-800. DOI: 10.1212/wnl.58.12.1791. View

13.

Cork L, Masters C, Beyreuther K, Price D . Development of senile plaques. Relationships of neuronal abnormalities and amyloid deposits. Am J Pathol. 1990; 137(6):1383-92. PMC: 1877724. View

14.

Thal D, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K . Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000; 59(8):733-48. DOI: 10.1093/jnen/59.8.733. View

15.

Maldjian J, Daunais J, Friedman D, Whitlow C . Vervet MRI atlas and label map for fully automated morphometric analyses. Neuroinformatics. 2014; 12(4):543-50. PMC: 4939823. DOI: 10.1007/s12021-014-9231-8. View

16.

Herholz K, Salmon E, Perani D, Baron J, Holthoff V, Frolich L . Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002; 17(1):302-16. DOI: 10.1006/nimg.2002.1208. View

17.

Chen J, Fears S, Jasinska A, Huang A, Al-Sharif N, Scheibel K . Neurodegenerative disease biomarkers Aβ, Aβ, tau, and p-tau in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy. Brain Behav. 2018; 8(2):e00903. PMC: 5822592. DOI: 10.1002/brb3.903. View

18.

Shively C, Register T, Adams M, Golden D, Willard S, Clarkson T . Depressive behavior and coronary artery atherogenesis in adult female cynomolgus monkeys. Psychosom Med. 2008; 70(6):637-45. PMC: 3970186. DOI: 10.1097/PSY.0b013e31817eaf0b. View

19.

Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L . Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med. 2004; 45(2):192-201. View

20.

Woods R, Fears S, Jorgensen M, Fairbanks L, Toga A, Freimer N . A web-based brain atlas of the vervet monkey, Chlorocebus aethiops. Neuroimage. 2010; 54(3):1872-80. PMC: 3008312. DOI: 10.1016/j.neuroimage.2010.09.070. View